Matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in the peripheral blood of patients with various glomerular diseases and their implication in pathogenetic lesions: Study based on an enzyme-linked assay and immunohistochemical staining

被引:21
|
作者
Endo T. [1 ]
Nakabayashi K. [1 ]
Sekiuchi M. [1 ]
Kuroda T. [1 ]
Soejima A. [1 ]
Yamada A. [1 ]
机构
[1] First Department of Internal Medicine, Kyorin University, School of Medicine, Mitaka, Tokyo 181-8611
关键词
Glomerulonephritis; Metalloproteinase; Tissue inhibitor of metalloproteinase;
D O I
10.1007/s10157-006-0438-3
中图分类号
学科分类号
摘要
Background. Various glomerular diseases progress to end-stage renal failure due to an accumulation of the mesangial matrix (MM) and a thickening of the glomerular basement membrane (GBM). Both the MM and GBM are consistently metabolized through the synthesis and destruction of the matrix. Such synthesis is influenced by transforming growth factor-β (TGF-β) and other factors, whereas the destruction is presumed to be mediated by both matrix metalloproteinases (MMPs) and inhibitors of matrix metalloproteinases (TIMPs). Based on such evidence, we tried to detect MMP-2, MMP-9, and TIMP-1 in the peripheral blood of patients with various glomerular diseases. Methods. Serum was used to detect MMP-2 and TIMP-1, while plasma was used to detect MMP-9. These enzymes were detected using an enzyme-linked assay. Results. The findings showed an increased level of MMP-2 in patients with a alteration of GBM, typically membranous nephropathy (MN), regardless of the differences in their etiological processes. In contrast, MMP-9 did not show a strong association with any specific glomerular abnormalities. However, it mainly tended to increase in patients with MM accumulation. In addition, the localization of MMP-2, MMP-9, and TGF-β1 was studied using immunohistochemical staining. MMP-2 was demonstrated to exist in the glomerular capillary loop (GCL) as well as in the mesangial cells and the mesangial matrix. MMP-9 was found to exist in mesangial cells and the matrix, GCL, infiltrated neutrophils, and some tubular epithelial cells. Positive staining for TGF-β1 in GCL was found to be associated with an increased level of MMP-2 in patients with MN, whereas in MM such positive staining was not necessarily associated with an increased level of MMP-9. Conclusions. These results therefore suggest that MMP-2 plays an important role in the degradation of GBM, while MMP-9 only moderately affects the degradation of MM. © 2006 Japanese Society of Nephrology.
引用
收藏
页码:253 / 261
页数:8
相关论文
共 50 条
  • [1] Correlations between papillary thyroid cancer and peripheral blood levels of matrix metalloproteinase-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and tissue inhibitor of metalloproteinase-2
    Zhou Shao-fei
    Hu San-yuan
    Ma Lei
    Miao Lei
    Mao Wei-zheng
    CHINESE MEDICAL JOURNAL, 2013, 126 (10) : 1925 - 1929
  • [2] Matrix metalloproteinase-2,-9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension
    Derosa, Giuseppe
    D'Angelo, Angela
    Ciccarelli, Leonardina
    Piccinni, Mario N.
    Pricolo, Fabio
    Salvadeo, Sibilla
    Montagna, Lorenza
    Gravina, Alessia
    Ferrari, Ilaria
    Galli, Simona
    Paniga, Sonia
    Tinelli, Carmine
    Cicero, Arrigo F. G.
    ENDOTHELIUM-JOURNAL OF ENDOTHELIAL CELL RESEARCH, 2006, 13 (03): : 227 - 231
  • [3] Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure
    George, J
    Patal, S
    Wexler, D
    Roth, A
    Sheps, D
    Keren, G
    AMERICAN HEART JOURNAL, 2005, 150 (03) : 484 - 487
  • [4] Expression of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Endometriosis Menstrual Blood
    Madjid, Tita Husnitawati
    Ardiansyah, Dennis Fachmi
    Permadi, Wiryawan
    Hernowo, Bethy
    DIAGNOSTICS, 2020, 10 (06)
  • [5] Expression of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1, and Changes in Alveolar Septa in Patients with Chronic Obstructive Pulmonary Disease
    Zhang, Yongxiang
    Li, Yuechuan
    Ye, Zhen
    Ma, Hui
    MEDICAL SCIENCE MONITOR, 2020, 26 : e925278
  • [6] Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and-2 in type 2 diabetes
    Tayebjee, MH
    Lim, HS
    MacFadyen, R
    Lip, GYH
    DIABETES CARE, 2004, 27 (08) : 2049 - 2051
  • [7] Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans
    Dellalibera-Joviliano, Renata
    Jacob-Ferreira, Anna L. B.
    Joviliano, Edwaldo Edner
    Tanus-Santos, Jose E.
    Evora, Paulo R. B.
    VASCULAR MEDICINE, 2012, 17 (02) : 73 - 78
  • [8] Plasma matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 as prognostic biomarkers in critically ill patients
    Duda, Izabela
    Krzych, Lukasz
    Jedrzejowska-Szypulka, Halina
    Lewin-Kowalik, Joana
    OPEN MEDICINE, 2020, 15 (01): : 50 - 56
  • [10] CELL DISTRIBUTION DIFFERENCES OF MATRIX METALLOPROTEINASE-9 AND TISSUE INHIBITOR OF MATRIX METALLOPROTEINASE-1 IN PATIENTS WITH KAWASAKI DISEASE
    Korematsu, Seigo
    Ohta, Yoko
    Tamai, Naotaka
    Takeguchi, Masahiro
    Goto, Chika
    Miyahara, Hiroaki
    Kawano, Tatsuya
    Izumi, Tatsuro
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (09) : 973 - 974